Recent nanotechnological aspects in cosmetics and dermatological preparations

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 2, 2012, Pages 88-97

  Bangale, M S ^a   Mitkare, S S ^a   Gattani, S G ^a   Sakarkar, D M ^b  

^a SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

^b SN Institute of Pharmacy   (India)

Author keywords

Cosmetic and dermal preparation; Nanotechnology; Skin penetration

Indexed keywords

ASCORBIC ACID; COSMETIC; DERMATOLOGICAL AGENT; DRUG CARRIER; GLUCOCORTICOID; GOLD; INSULIN; LIPID; NANOFIBER; NANOMATERIAL; NANOPARTICLE; NEOBENZ MICRO WASH PLUS PACK[R]; NEOBENZ MICRO[R]; POLYGLACTIN; SOLID LIPID NANOPARTICLE; SUNSCREEN; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; VITAMIN; ZINC OXIDE;

ATOPIC DERMATITIS; CONTACT DERMATITIS; DRUG DELIVERY SYSTEM; DRUG TARGETING; HAIR DISEASE; HUMAN; NANOTECHNOLOGY; REVIEW; SKIN ABSORPTION; SKIN ATROPHY;

EID: 84859945811     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (196)

1. Morganti P, Use and potential of nanotechnology in cosmetic dermatology. Clin Cosmet Investig Dermatol 2010;3 5-13
2. Morganti P, Morganti G, Yuanhong Li Nanostructured products: technology and future. Journal of Applied Cosmetology. 2007; 25(4): 161-178.
3. http://dictionary.reference.com
4. Gautam A., Singh, Vijayaraghavan R, Dermal Exposure of Nanoparticles: An Understanding. Journal of Cell and Tissue Research 2011; 11(1): 2703-2708.
5. http://www.namo.gov
6. Ochekpe NA, Olorunfemi PO and Ngwuluka NC. Nanotechnology and Drug Delivery Part 1: Background and Applications
7. Stylios GK, Giannoudis PV, Wan T. Applications of nanotechnologies in medical practice. Injury, 2005; 36 (4, Suppl. 1): S6-S13.
8. The Royal Society and the Royal Academy of Engineering. Nanoscience and Nanotechnologies. The Royal Society and the Royal Academy of Engineering Report, July 2004. http://www.nanotec.org.uk/finalReport.htm Accessed 05 August, 2008.
9. Suphiya Parveen, MS, Ranjita Misra, MS, Sanjeeb K. Sahoo, PhD Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging, Nanomedicine, 2011
10. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine 2007; 3: 20-31.
11. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003; 8:1112-20.
12. http://iopscience.iop.org/0957-4484/14/1/001
13. http://www.becon.nih.gov/nstc_def_nano.htm
14. Preliminary opinion on safety of Nanomaterials In Cosmetic Products; Approved by the SCCP for public consultation 12th plenary of 19 June 2007
15. Gerhard J. Nohynek, J̈urgen Lademann, Christele Ribaud, Michael S. Roberts, Grey Goo on the Skin? Nanotechnology, Cosmetic and Sunscreen Safety, Crit Rev Toxicol 2007; 37:251-277.
16. SCENIHR, 2005. Nel et al., 2006.
17. Sudhamani T, Priyadarisini N, Radhakrishnan M, Proniosomes - A Promising Drug Carrier. International Journal of PharmTech Research. 2010; 2(2)
18. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status
19. Papakostas D, Rancan F, Sterry W, Blume-Peytavi U, Vogt A, Nanoparticles in dermatology. Arch Dermatol Res 2011; 303:533-550.
20. BBC Research 2007.
21. Patidar A, Thakur DS, Kumar P, Verma J. A Review on Novel Lipid Based Nanocarriers. International Journal of Pharmacy and Pharmaceutical Sciences 2010; 2(4).
22. Chen, X. and Schluesener, H.J.: Toxicol Lett 2008; 176: 1-12.
23. Rotoli B.M, Bussolati O, Bianchi MG, Barilli A, Balasubramanian C, Bellucci S. Bergamaschi E. Toxicol Lett 2008; 178: 95-102.
24. Crosera M, Bovenzi M, Maina G, Adami G, Zanette C, Florio C, Larese F.F. International Achieves of Occupational and Environmental Health 2009; 82: 1043-1055.
25. Fiserova-Bergerova, V, Pierce JT, Droz PO. American Journal of Industrial Medicine 1990; 17: 617-635.
26. Nielsen JB, Grandjean P. American Journal of Industrial Medicine 2004; 45: 275-280.
27. Sartorelli P, Ahlers HW, Alanko K, Chen-Peng C, Cherrie JW, Drexler H, Kezic S, Johanson G, Larese Filon F, Maina G, Montomoli L, Nielsen J.B. Regulatory Toxicology and Pharmacology 2007; 49: 301-307.
28. Baroli B. Journal of Pharmaceutical Sciences 2010; 99: 21-50.
29. Baroli B, Ennas MG, Loffredo F, Isola M, Pinna R, Lopez-Quintela A. J Investig Dermatol 2007; 127:1701-1712.
30. Wagner H, Kostka KH, Lehr CM, Schaefer U.F. Eur J Pharm Biopharm 2003; 55: 57-65.
31. Elias PM. J Investig Dermatol 2005; 125: 183-200.
32. Benson HA. Current Drug Delivery 2005; 2: 23-33.
33. Vavrova K, Zbytovska J, Hrabalek A. Curr Med Chem 2005; 12: 2273-2291.
34. Gonzalez S, Fernandez-Lorente M, Gilaberte-Calzada Y. The latest on skin hotoprotection. Clin Dermatol 2008; 26:614-626.
35. Cross SE, Innes B, Roberts MS, Tsuzuki T, Robertson TA, McCormick P. Human skin penetration of sunscreen nanoparticles: in vitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol Physiol 2007; 20:148-154.
36. Lademann J, Weigmann H, Rickmeyer C, Barthelmes H, Schaefer H, Mueller G, Sterry W. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin. Physiol 1999; 12:247-256.
37. Newman MD, Stotland M, Ellis JI. The safety of nanosized particles in titanium dioxide-and zinc oxide-based sunscreens. J Am Acad Dermatol 2009; 61:685-692.
38. Mortensen LJ, Oberdörster G, Pentland AP, Delouise LA. In vivo skin penetration of quantum dot nanoparticles in the murine model: the effect of UVR. Nano Lett 2008; 8:2779-2787.
39. Durand L, Habran N, Henschel V, Amighi K. Encapsulation of ethylhexyl methoxycinnamate, a light-sensitive UV filter, in lipid nanoparticles. J Microencapsul 2010; 27(8):714-725.
40. Xia Q, Saupe A, Muller RH, Souto EB. Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int J Cosmet Sci 2007; 29:473-482.
41. Alvarez-Roman R, Barre G, Guy RH, Fessi H. Biodegradable polymer nanocapsules containing a sunscreen agent: preparation and photoprotection. Eur J Pharm Biopharm 2001; 52:191-195.
42. Padamwar MN, Pokharkar VB. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability. Int J Pharm 2006; 320:37-44.
43. De Fine Olivarius F, Hansen AB, Karlsmark T, Wulf HC. Water protective effect of barrier creams and moisturizing creams: a new in vivo test method. Contact Dermatitis 1996; 35:219-225.
44. Kato S, Taira H, Aoshima H, Saitoh Y, Miwa N. Clinical evaluation of fullerene-C60 dissolved in squalane for antiwrinkle cosmetics. J Nanosci Nanotechnol 2010; 10(10):6769-6774.
45. Lboutounne H, Chaulet JF, Ploton C, Falson F, Pirot F. Sustained ex vivo skin antiseptic activity of chlorhexidine in poly(epsiloncaprolactone) nanocapsule encapsulated form and as a digluconate. J Control Release 2002; 82:319-334.
46. Lboutounne H, Faivre V, Falson F, Pirot F Characterization of transport of chlorhexidine-loaded nanocapsules through hairless and wistar rat skin. Skin Pharmacol Physiol 2004; 17:176-182.
47. Henderson BW, Dougherty TJ. How does photodynamic therapy work? J Photochem Photobiol 1992; 55:145-157.
48. Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis C, Blume-Peytavi U, Schafer-Korting M. RU 58841-myristate-prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie 2005; 60:8-12.
49. Shim J, Seok KH, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release 2004; 97:477-484.
50. Tsujimoto H, Hara K, Tsukada Y, Huang CC, Kawashima Y, Arakaki M, Okayasu H, Mimura H, Miwa N. Evaluation of the permeability of hair growing ingredient encapsulated PLGA nanospheres to hair follicles and their hair growing effects. Bioorg Med Chem Lett 2007; 17:4771-4777.
51. Jenning V, Gysler A, Schafer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49:211-218.
52. Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol 2000; 5:455-464.
53. Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H. Sitespecific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 1993; 10:1738-1744.
54. Bikowski J, Del Rosso JQ. Benzoyl peroxide microsphere cream as monotherapy and combination treatment of acne. J Drugs Dermatol 2008; 7:590-595.
55. Santos MC, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schafer-Korting M. Drug targeting by solid lipid nanoparticles for dermal use. J Drugs Dermatol 2002; 10:489-495.
56. Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit 2008; 14(12):I66-I74.
57. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, Yang Y, Xu H, Yang X. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006; 110:296-306.
58. Egbaria K, Ramachandran C, Weiner N. Topical application of liposomally entrapped cyclosporin evaluated by invitro diffusion studies with human skin. Skin Pharmacol 1991; 4:21-28.
59. Erdogan M, Wright JR Jr, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for treatment of immunemediated skin disorders: experimental studies in a murine model. Br J Dermatol 2002; 146:964-967.
60. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008; 70:633-640.
61. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat 2007; 18:40-45.
62. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278:71-77.
63. Vogt A, Mandt N, Lademann J, Schaefer H, Blume-Peytavi U. Follicular targeting-a promising tool in selective dermatotherapy. J Investig Dermatol Symp Proc 2005; 10:252-255.
64. Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005; 57:333-355.
65. Combadiere B, Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 2008; 31:293-315.
66. Lawson LB, Freytag LC, Clements JD. Use of nanocarriers for transdermal vaccine delivery. Clin Pharmacol Ther 2007; 82:641-643.
67. Rastogi R, Anand S, Koul V. Electroporation of polymeric nanoparticles: an alternative technique for transdermal delivery of insulin. Drug Dev Ind Pharm 2010; 36(11):1303-1311.
68. Ballou B, Ernst LA, Andreko S, Harper T, Fitzpatrick JA, Waggoner AS, Bruchez MP Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug Chem 2007; 18:389-396.
69. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta 2005; 358:37-54.
70. Olafsson R, Bauer DR, Montilla LG, Witte RS. Realtime, contrast enhanced photoacoustic imaging of cancer in a mouse window chamber. Opt Express 2010; 18(18):18625-18632.
71. Mukherjee S, Ghosh RN, Maxfield FR. Physiol Rev 1997; 77: 759-803.
72. Aderem A, Underhill DM. Annu Rev Immunol 1999; 17: 593-623.
73. Gruenberg J. Nature Reviews Molcular Cell Biology 2001; 2: 721-730.
74. Scott CC, Botelho RJ, Grinstein S. J Membr Biol 2003; 193: 137-152.
75. Puri D, Bhandari A, Sharma P, Choudhary D. Lipid Nanoparticles (Sln, Nlc): A Novel Approach For Cosmetic And Dermal Pharmaceutical. Journal of Global Pharma Technology. 2010; 2(5):1-15.
76. Müller RH, Lucks JS, Arzneistoffträger aus festen Lipidteilchen- Feste. Lipid Nanosphären (SLN). 1996; EP 0605497.
77. Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005; 6:3-5.
78. Lucks JS. Medication vehicles made of solid lipid particles (solid lipid Nanospheres SLN).EP0000605497, 1991.
79. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56:1257-72.
80. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carryingdoxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000; 42:337-43.
81. Maia CS, Mehnert W, Schafer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 2000; 196:165-7.
82. Mistry SN, Patel PK, Bharadia PD, Pandya VM, Modi DA, Delivery Novel Drug System For Lipophilic Agents: Solid Lipid Nanoparticles. Ijpi's Journal of Pharmaceutics and Cosmetology 2011; 1: 4.
83. Santos Maia C, Mehnert W, Schäfer-Korting M. Solid lipid nanoparticles as drug carrier for topical glucocorticoids. Int. J. Pharm 2000; 196: 165-167.
84. Iraji F, Momeni A, Naji SM, Siadat AH. The efficacy of topical cyproterone acetate alcohol lotion versus placebo in the treatment of the mild to moderate acne vulgaris: a double blind study. Dermatol. Online J 2006; 12:26.
85. Stecova, J., Mehnert, W., Blaschke, T., Kleuser, B., Sivaramakrishnan, R., Zouboulis, C.C., Seltmann, H., Korting, H.C., Kramer, K.D., Schafer-Korting, M. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm. Res. 2007; 24: 991-1000.
86. Santos MC, Mehnert W, Schaller M. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002; 10:489-95.
87. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate. Loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 2006; 6:2991-5.
88. Jenning V, Schafer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000; 66: 115-26.
89. Pandey R, Sharma S, Khuller GK. Oral SLN Based antitubercular chemotherapy. Tuberculosis (Edinb) 2005; 85: 415-20.
90. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur. J. Pharm. Biopharm 2003; 56:189-196.
91. Müller RH. Mehnert W, Souto EB. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery. In: Bronaugh, R.L. (Ed.), Percutaneous Absorption 2005; 4:719-738.
92. Gohla SH, Dingler A. Scaling up feasibility of the production of solid lipidnanoparticles (SLN). Pharmazie 2001; 56: 61-63.
93. Schwarz C, Mehnert W, Lucks JS, Müller, RH. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J. Contr. Rel 1994; 30: 83-96.
94. Cavalli R, morel S, Gasco MR, Chetoni P, Saettone MF. Int. J. Pharm 1995; 117-243.
95. Gasco MR, Morel S, Farmaco 1990; 45(Oct):1127.
96. Gasco MR, Cavalli R, Carlotti ME. Pharmazie 1992a; 47:119.
97. Gasco MR, Morel S, Carpignano R. Eur. J. Pharm. Biopharm 1992 b; 38:7.
98. Shah DS, In: Macro and microemulsion, Theories and application, A.C.S. Symposium Series 1985.
99. Cavalli R, Caputo O, Gasco MR, Int. J. Pharm 1993; 89:R9.
100. Mishra B, Pandit JK, Tiwari P. Eastern Pharmasist 1988; XXXI: 77.
101. Khopade AJ, Jain NK. Pharmazie 1996; 51:558.
102. Florence AT, Whitehill D. Int. J. Pharm 1982; 11:277.
103. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and congealed lipid microparticles and characterization of their surface morphology by scanning electron microscopy. Pharm Res 1991; 8:47-54.
104. Speiser P. Lipidnanopellets als Tragersystem fur Arzneimittel zur peroralem Anwendung. European Patent No. EP 0167825; 1990.
105. Chen YJ, Jin RX, Zhou YQ, Zeng J, Zhang H, Feng QR. Preparation of solid lipid nanoparticles loaded with Xionggui powdersupercritical carbon dioxide fluid extraction and their evaluation in vitro release. Zhongguo Zhong Yao Za Zhi 2006; 31:376-9.
106. Kaiser CS, Rompp H, Schmidt PC.Pharmaceutical applications of supercritical carbon dioxide. Pharmazie 2001; 56: 907-26.
107. Gosselin PM, Thibert R, Preda M, McMullen JN. Polymeric properties of micronized carbamazepine produced by RESS. Int J Pharm 2003; 252:225-33.
108. Sjostrom B, Bergenstahl B. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions: I: Model studies of the precipitation of cholesteryl acetate. Int J Pharm 1992; 88: 53-62.
109. Siekmann B, Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J Pharm Biopharm 1996; 43: 104-9.
110. Cortesi R, Esposito E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials 2002; 23:2283-94.
111. Freitas C, Muller RH. Spray-drying of Solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm 1998; 46: 145-51.
112. Muller RH, Weyhers H, Muhlen A, Dingler A, Mehnert W. Solid lipid nanoparticles (SLN)-einneuartiger Wirkstoff-Carrier furKosmetika and Pharmazeutika: I. Systemeigenschaften, Herstellung und Scaling up, Pharm Ind. 1997; 59 (5): 423-427.
113. Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 2007; 59:427-443.
114. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, and Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm. Sci 2003; 92: 1085 -1094.
115. Freitas C, Müller RH. Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencap 1999; 16: 59-71.
116. Gohla SH, Dingler A. Scaling up feasibility of the production of solid lipidnanoparticles (SLN). Pharmazie 2001; 56: 61-63.
117. Fundarò A. Non-stealth and stealth solid lipid nanoparticles carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacological Research 2000; 42; 337-343.
118. Chen DB, Yang TZ, Lu WL, and Zhang Q. In vitro study of two types of long circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 2001; 49:1444-1447.
119. Tabatt K. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release 2004; 97: 321-332.
120. Cavalli R, Caputo O, and Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000; 10: 305-309.
121. Müller RH, Mäder, and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
122. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 1993; 89:R9-R12.
123. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002; 242: 121-128.
124. Muller RH, Runge SA. Solid lipid nanoparticles (SLN) for controlled drug delivery. In: Benita S, editor. Submicron emulsions in drug targeting and delivery, Amsterdam: Harwood Academic Publishers 1998; 219-34.
125. Jenning V, Gysler A, Schafer-Korting M, Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use: Occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49:211-8.
126. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131-55.
127. Santos Maia C, Mehnert W, Schäfer-Korting M. Solid lipid nanoparticles as drug carrier for topical glucocorticoids. Int. J. Pharm 2000; 196:165-167.
128. Iraji F, Momeni A, Naji SM, Siadat AH. The efficacy of topical cyproterone acetate alcohol lotion versus placebo in the treatment of the mild to moderate acne vulgaris: a double blind study. Dermatol. Online J 2006; 12:26.
129. Stecova, J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis, CC, Seltmann H, Korting HC, Kramer KD, Schafer-Korting M. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 2007; 24: 991-1000.
130. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006; 110: 296-306.
131. Jenning V, Schafer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000; 66: 115-26.
132. Santos MC, Mehnert W, Schaller M. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002; 10:489-95.
133. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 2003; 56: 189-196.
134. Pandey R, Sharma S, Khuller GK. Oral SLN Based antitubercular chemotherapy. Tuberculosis (Edinb) 2005; 85: 415-20.
135. Wissing SA, Muller RH. Solid lipid nanoparticles (SLN) a novel carrier for UV blockers. Pharmazie 2001; 56:783-6.
136. Rudolph C, Schillinger U, Ortiz A, Tabatt K, Plank C, Muller RH, et al. Application of novel Solid lipid nanoparticles (SLN) -gene vector formulations based on a diametric HIV-1 VAT -peptide invitro and invivo. Pharmaceutic Res 2004; 21:1662-9.
137. Lu B, Xiong SB, Yang H., Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymphnode metastases. Eur J Pharm Sci 2006; 28:86-95.
138. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 2006; 6:2991-5.
139. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999; 59:299-307.
140. Wang Y, Wu W. In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv 2006; 13:189-92.
141. Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A, Gasco MR. Int J Pharm 1988; 175:185.
142. Lai F, Wissing SA, Muller RH, Fadda AM. Artemisia arborescens L essential oil-loaded solid lipid nanoparticles for potential agriculture application: Preparation and characterization. AAPS Pharm Sci Tech 2006; 7:E2.
143. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev.2001; 47:165-196.
144. Müller RH, Souto EB, Radtke M. Nanostructured Lipid Carriers:A Novel Generation of Solid Lipid Drug Carriers. Pharmaceutical Technology Europe. 2005; 17(4): 45-50.
145. Müller RH, Souto EB, Radtke M. PCT application PCT/EP00/04111: 2000.
146. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipidnanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J Control Release, 1994; 30: 83-96.
147. Muiller RH, Mehnert W, Lucks JS, Schwarz C, Miihlen A, Weyhers H, Freitas C, Riihl D. Solid lipid nanoparticles (SLN)--an alternative colloidal carrier system for controlled drugdelivery. Eur J Pharm Biopharm. 1995; 41: 62-69.
148. Pardeike J, Hommoss A, Müller RH, Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products, Int J Pharm 2009; 366:170-184.
149. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products, Adv Drug Deliv Rev 2007; 59:522-530.
150. Muller RH, Pardeike J, Hommoss A. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366:170-184.
151. Panwar AS, Yadav CS, Yadav P, Darwhekar GN, Jaina DK, Panwar MS, Agrawal A. Microsponge A Novel Carrier for Cosmetics, Journal of Global Pharma Technology. July 2011; 3(7):15-24.
152. Aritomi H, Yamasaki Y, Yamada K, Honda H, Koshi M. Development of sustained release formulation of chlorpheniramine maleate using powder coated microsponges prepared by dry impact blending method. Journal of Pharmaceutical Science and Technology, 1996; 56(1): 49-56.
153. Patel G, Patel JK. Use of a Microsponge in Drug Delivery Systems. Pharmaceutical processing, 2008, 158.
154. Nacht S, Katz M. The microsponge: a novel topical programmable delivery system. In: Osborne DW, Amann AH, editors. Topical drug delivery formulations. New York: Marcel Dekker 1990; 299-325.
155. D'souza JI. The Microsponge Drug Delivery System: For Delivering an Active Ingredient by Controlled Time Release. 2008; 6 (3): 62; 19.
156. Shah VP. Determination of In-vitro release from hydrocortisone creams. Int J Pharm. 1989; 53:53-59.
157. Amrutiya N, Bajaj A, Madan M. AAPS PharmSciTech 2009; 10(2):402-09.
158. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation 2004; 74(6):362-8.
159. D'souza JI, Harinath NM. Topical anti-inflammatory gels of fluocinolone acetonide entrapped in eudragit based microsponge delivery system. Research Journal of Pharmacy and Technology 2008; 1(4):502-6.
160. Jain V, Singh R. Development and characterization of eudragit RS 100 loaded microsponges and its colonic delivery using natural polysaccharides. Acta Poloniae Pharmaceutica. Drug Research 2010; 67:407-15.
161. Jain V, Singh R. Dicyclomine-loaded Eudragit ® -based microsponge with potential for colonic delivery: preparation and characterization. Tropical Journal of Pharmaceutical Research. 2010; 9(1):67-72.
162. Chen G, Ushida T, Tateishi T. Poly (DL-lactic-co-glycolic acid) sponge hybridized with collagen microsponges and deposited apatite particulates. Journal of Biomedical Materials Research 2001; 57(1):8-14.
163. Iwai S, Sawa Y, Ichikawa H, Taketani S, Uchimura E, Chen G., Hara M, Miyake J, Matsuda H. Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis. J Thorac Cardiovasc Surg. 2004; 128(3):472-9.
164. D'souza JI, Harinath NM. The Microsponge Drug Delivery System: For Delivering an Active Ingredient by Controlled Time Release. Pharmaceutical Reviews 2008; 6(3),
165. Anahita Fathi-Azarbayjani, Lin Qun, Yew Weng Chan, Sui Yung Chan. Novel Vitamin and Gold-Loaded Nanofiber Facial Mask for Topical Delivery. AAPS PharmSciTech 2010; 11.
166. Segall AI, Moyano MA. Stability of vitamin C derivatives in topical formulations containing lipoic acid, vitamins A and E. Int J Cosmet Sci. 2008; 30:453-8.
167. Gaspar LR, Campo PMBGM. Photostability and efficacy studies of topical formulations containing UV-filters combination and vitamins A C and E. Int J Pharm 2007; 343:181-9.
168. Watson REB, Long SP, Bowden JJ, Bastrilles JY, Barton SP, Griffiths CEM. Repair of photoaged dermal matrix by topical application of a cosmetic 'antiageing' product. Br J Dermatol 2008; 158:472-7.
169. Cao C, Wan S, Jiang Q, Amaral A, Lu S, Hu G, et al. All-trans retinoic acid attenuates ultraviolet radiation-induced downregulation of aquaporin-3 and water permeability in human keratinocytes. J Cell Physiol 2008; 215:506-16.
170. Kang S, Voorhees JJ. Photoaging therapy with topical tretinoin, an evidence based analysis. J Am Acad Dermatol 1998; 39: S55-61.
171. Fisher GJ, Kang S, Varani J, Bata-Csorgo Z, Wan Y, Datta S, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol 2002; 138:1462-70.
172. Thielitz A, Abdel-Naser MB, Fluhr JW, Zouboulis CC, Gollnick H. Topical retinoids in acne: An evidence-based overview. J Dtsch Dermatol Ges 2008; 6:1023-31.
173. Lin HS, Chean CS, Ng YY, Chan SY, Ho PC. 2-Hydroxypropylbcyclodextrin increases aqueous solubility and photostability of all-trans-retinoic acid. J Clin Pharm Ther 2000; 25:265-9.
174. Montassier P, Duchene D, Poelman MC. Inclusion complexes of tretinoin with cyclodextrins. Int J Pharm 1997; 153:199-209.
175. Hu LD, Tang X, Cui FD. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmocol 2004; 56:1527-35.
176. Sonavane G, Tomoda K, Sano A, Ohshima H, Terada H, Makino K. In vitro permeation of gold nanoparticles through rat skin and rat intestine: Effect of particle size. Colloids Surf B Biointerfaces 2008; 65:1-10.
177. Menon GK, Brandsma JL, Schwartz PM. Particle-mediated gene delivery and human skin: Ultrastructural observations on stratum corneum barrier structures. Skin Pharmacol Physio. 2007; 20:141-7.
178. Mulholland WJ, Arbuthnott EAH, Bellhouse BJ, Cornhill JF, Austyn JM, Kendall MAF, et al. Multiphoton high-resolution 3d imaging of langerhans cells keratinocytes in the mouse skin model adopted for epidermal powdered immunization. J Invest Dermatol 2006; 126:1541-8.
179. Dean HJ, Haynes J, Schmaljohn C. The role of particle-mediated DNAvaccines in biodefense preparedness. Adv Drug Deliv Rev 2005; 57:1315-42.
180. Verreck G, Chun I, Rosenblatt J, Peeters J, Dijck AV, Mensch J, et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of water-insoluble, nonbiodegradable polymer. J Control Release 2003; 92:349-60.
181. Taepaiboon P, Rungsardthong U, Supaphol P. Vitamin-loaded electrospun cellulose acetate nanofiber mats as transdermal and dermal therapeutic agents for vitamin A acid and vitamin E. Eur J Pharm Biopharm 2007; 67:387-97.
182. 2) Nano-Particles: A Societal Experiment. Nanoethics 2010; 4:103-113.
183. Thomas Faunce & Katherine Murray & Hitoshi Nasu & Diana Bowman, Sunscreen Safety: The Precautionary Principle, The Australian Therapeutic Goods Administration and Nanoparticles in Sunscreens, Nanoethics 2008; 2:231-240.
184. Troy M. Benn, Paul Westerhoff, Pierre Herckes, Detection of fullerenes (C60 and C70) in commercial cosmetics Environmental Pollution 159 2011; 1334:1342.
185. Halford, 2006
186. Woodrow Wilson International Center for Scholars, 2009
187. Xiao et al., 2006.
188. Johansen et al., 2008
189. Kai et al., 2003
190. Miyata et al., 2000
191. Tsuchiya et al., 1996
192. Usenko et al., 2008.
193. Spohn et al., 2009.
194. Benotti et al., 2009.
195. Halford, 2006.
196. National Science and Technology Council, 2006.